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• Neonatal MSG administration induced anxiogenic-like behavior in adult rats.
• (PhSe)2 elicited an anxiolytic-like behavior in rats exposed to MSG.
• (PhSe) reversed the increase in hippocampal GABA and 5-HT uptake induced by MSG.
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Available online 2 December 2015Monosodium glutamate (MSG), a ﬂavor enhancer used in food, administered to neonatal rats causes neuronal le-
sions and leads to anxiety when adulthood.
Aims:We investigated the anxiolytic-like effect of diphenyl diselenide (PhSe)2 and itsmechanisms on anxiety in-
duced by MSG.
Main methods: Neonatal male and female Wistar rats received a subcutaneous injection of saline (0.9%) or MSG
(4 g/kg/day) from the 1st to 10th postnatal day. At 60 days of life, the rats received (PhSe)2 (1mg/kg/day) or ve-
hicle by the intragastric route for 7 days. The spontaneous locomotor activity (LAM), elevated plus maze test
(EPM) and contextual fear conditioning test (CFC) as well as neurochemical ([3H]GABA and [3H]5-HT uptake)
and molecular analyses (Akt and p-Akt and BDNF levels) were carried out after treatment with (PhSe)2.
Key ﬁndings:Neonatal exposure toMSG increased all anxiogenic parameters in LAM, EPM and CFC tests. MSG in-
creased GABA and 5-HT uptake in hippocampus of rats, without changing uptake in cerebral cortex. The levels of
BDNF and p-Akt were reduced in hippocampus of rats treated with MSG. The administration of (PhSe)2 to rats
reversed all behavioral anxiogenic parameters altered by MSG. The increase in hippocampal GABA and 5-HT up-
take induced by MSG was reversed by (PhSe)2. (PhSe)2 reversed the reduction in hippocampal BDNF and p-Akt
levels induced by MSG.
Signiﬁcance: In conclusion, the anxiolytic-like action of (PhSe)2 in rats exposed to MSG during their neonatal pe-
riod is related to its modulation of hippocampal GABA and 5-HT uptake as well as the BDNF-Akt pathway.
© 2015 Elsevier Inc. All rights reserved.Keywords:
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Monosodium glutamate (MSG), the sodium salt of glutamic acid, is
widely used as a ﬂavor enhancer in human diets [1], making its toxicity
a signiﬁcant area of animal and human research.ica e biologia molecular, Centro
Santa Maria, Santa Maria, CEPThe administration of MSG in animals during the neonatal period,
when the blood brain barrier is not fully developed, leads to destruction
of neuronal cell bodies located in the central nervous system (CNS), pro-
ducing damage in various brain regions [2,3]. Consequently, upon
reaching adulthood these animals exhibit behavioral deﬁcits [4,5] and
neurochemical disturbances [6,7].
The neuronal networks in the vertebrate brain consist of excitatory
principal neurons (glutamatergic) and inhibitory interneurons
(GABAergic), which interact to establish a functional balance avoiding
the appearance of disease [8]. The GABAergic systemmay be considered
an important target for MSG excitotoxicity, once those GABAergic
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neurons [9,10]. Moreover, it has been demonstrated that neonatal ad-
ministration of MSG alters [3H]GABA release and total glutamic acid de-
carboxylase (GAD) activity [11] in different brain regions.
It is known that GABAergic dysfunction is strongly implicated in
anxiety [12,13], a serious disorder with symptoms manifesting at the
psychological, behavioral and physiological levels. In this context, previ-
ous data demonstrated that neonatal administration of MSG induces
depressive-like and anxiogenic-like behaviors in young rats which
were related to the increase in the 5-hydroxytryptamin serotonin (5-
HT) uptake in cerebral cortices [6] and increased sensitivity of seroto-
ninergic neurons [14].
In addition to changes in neurotransmitter systems, brain-derived
neurotrophic factor (BDNF), a secretory protein of neurotrophin family,
has been implicated in the pathophysiology of anxiety disorders [15,16]
and has been explored as a potential target for the development of an-
xiolytic drugs [17]. The effects of BDNF may be mediated through the
binding of the tyrosine protein kinase B (TrKB) receptor, which leads
to activation of intracellular signaling, including the phosphatidyl inosi-
tol 3-kinase (PI-3K)-Akt phosphorylation [18], an important protein
that promotes cell survival [19].
In thisway, substances effective inmodulating different systems and
signaling pathways are of signiﬁcant interest as a potential treatment
for anxiety disorders. Over the past decade some organoselenium com-
pounds have been studied by our research group in view of their phar-
macological properties [20], such as neuroprotective [21], antioxidant
[22], anti-inﬂammatory, antinociceptive [23] and antidepressant-like
[24]. Among them, diphenyl diselenide has been reported as a potential
antidepressant- and anxiolytic-like agent [25,26] and these effects are
related to the modulation of GABAA and 5-HT receptors [27].
Considering the above mentioned, the aim of this study was to in-
vestigate the effect of diphenyl diselenide in the anxiety-like behavior
induced by MSG in rats as well as to demonstrate the involvement of
5-HT and GABA uptake and the BDNF-Akt pathway in this effect.2. Materials and methods
The experiments were carried out using male and female newborn
Wistar rats (pups weighing around 5 g) from our own breeding colony.
Pups were obtained from four different litters. Both male and female
rats were used based on our previous study [6]. The animals were
kept on a 12 h light/dark cycle with lights turned on every day at
7:00 a.m., at room temperature (22 ± 1 °C) with free access to water
and food. All behavioral tests were carried out between 08:00 a.m.
and 04:00 p.m. The present experimental studywas approved by the In-
stitutional Ethics Committee on Care and Use of Experimental Animal
Resources from the Federal University of Santa Maria-RS — Brazil and
registered under the number 028/2014. All efforts were made toFig. 1. Schematic representation of theminimize animal suffering and to reduce the number of animals used
in the experiments.
2.1. Drugs
Diphenyl diselenide (PhSe)2 was prepared in our laboratory accord-
ing to a previous method described [28]. 1H and 13C Nuclear Magnetic
Resonance Spectroscopy analysis showed analytical and spectroscopic
agreement with the assigned structures. The chemical purity of these
organoselenium compounds (99.9%) was determined by gas chroma-
tography–mass spectrometry (Shimadzu QP2010PLUS GC/MS combi-
nation). (PhSe)2 was dissolved in canola oil.
Monosodium glutamate (MSG) was purchased from Sigma–Aldrich
(St. Louis, MO, USA). All other chemicals were of analytical grade and
obtained from standard commercial suppliers.
2.2. Experimental design
Group-1 pups (n = 14 animals/group) received saline 1–10th day
and were kept undisturbed until 59th day. On 60th day, this group
was divided into two namely, control (received canola oil) and
(PhSe)2 (received test drug 1 mg/kg) for 7 consecutive days [5] (n =
7 animals/group).
Group-2 pups (n = 14 animals/group) received MSG (4 g/kg body
weight) once a day 1-10th day and were kept undisturbed until 59th
day. On 60th day, this group was divided into two namely, MSG (re-
ceived canola oil) and (PhSe)2 (received test drug 1 mg/kg) for seven
consecutive days [5] (n = 7 animals/group). Regarding the dose of
(PhSe)2 used in this study, repeated treatment with 1 mg/kg of
(PhSe)2 was chosen on the basis of the fact that this is an ineffective
dose of this compoundwhen administered as a single dose in ratmodels
of anxiety [25].
Thirty minutes after the last (PhSe)2 administration, the animals
were submitted to spontaneous locomotor activity monitor, the elevat-
ed plusmaze (EPM) test and the contextual fear conditioning test. Other
cohorts of rats were killed by decapitation without anesthesia in order
to extract the cerebral cortices and hippocampi, which were used for
ex vivo assays (Fig. 1).
2.2.1. Behavioral tests
2.2.1.1. Spontaneous locomotor activity. The rat spontaneous locomotor
activity was performed in order to discard non-speciﬁc effects of treat-
ments. The locomotor activity monitor (LAM) is a clear acrylic plastic
box (45 × 45 × 45 cm) with a removable plastic lid perforated with
holes for ventilation. The LAM (Model EP149, Insight Instruments
Ltda, Sao Paulo, BR) contains photocell beams and detectors that are
mounted on opposite walls (2 cm above the chamber ﬂoor). General lo-
comotor activity and the rat position in the chamber are detected byexperimental design of this study.
Table 1
Effect of (PhSe)2-treatment on spontaneous locomotor activity of rats administrated with MSG.
Locomotor parameters Control MSG (PhSe)2 MSG + (PhSe)2
Total distance traveled (mm) 5544 ± 1045 4421 ± 1260 4698 ± 689 2318 ± 570
Velocity (mm/s) 28.5 ± 3.8 21.4 ± 3.0 22.20 ± 2.9 18.87 ± 2.6
Values are reported as means ± S.E.M. for seven animals per group. Data were analyzed by using a two-way analysis of variance (ANOVA).
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recorded using a video tracking software (Software activity monitor In-
sight). Animals (n = 7 animals/group) were placed in the center of the
apparatus and allowed to freely explore the arena. Total distance trav-
eled (mm), velocity (mm/s) and time in the central square (s) were re-
corded for a 4 min period.
2.2.1.2. Anxiety-like behavior
2.2.1.2.1. EPM test. This test has been widely validated to measure
anxiety-like behavior in rodents [29]. The elevated plusmaze apparatus
consists of arms (length: 50 cm,width: 10 cm, height from ﬂoor: 50 cm)
in a cross-shaped form and a central region (10 cm2). Two of the arms
were enclosed on three sides by walls (height: 50 cm), whereas the
other two were not. The enclosed or open arms of the maze faced
each other. The maze is lit by a dim light placed above the central plat-
form. Each rat was placed at the center of the maze facing one of the
open arms and the number of entries, the time spent in the open arms
and the number of dives were recorded manually (using a stop
watch) by an experimenter during a 5min test period. An entrywas de-
ﬁned as placing all four paws within the boundaries of the arm. The an-
xiolytic effectiveness of a drug is illustrated by a signiﬁcant statistical
augmentation of parameters in open arms (time and/or entries) [30]
(n = 7 animals/group).
2.2.1.2.2. Contextual fear conditioning test. The contextual fear condi-
tioning test was performed as described by [31] with modiﬁcations.
During the contextual training phase, each rat received ten footshocks
(2.0 mA) with intervals of 20 s between the footshocks. Twenty-four
hours after training, rats were individually placed into the training
chamber and the time that animals spent exhibiting freezing was mea-
sured by an experimenter using a stop watch during 5 min. Freezing
was considered as a body immobility and the absence of vibrissae
movement associated with snifﬁng [32]. At the end of the test session,
the animals were removed from the chamber and returned to their
home cages (n = 7 animals/group).
2.2.2. Ex vivo assays
2.2.2.1. [3H]GABA uptake. The [3H]GABA uptake assay was carried out in
slices of cerebral cortices and hippocampi according to the method de-
scribed by Schweigert, de Oliveira [33]. Brainwas immediately removedFig. 2. Effect of neonatal MSG-injection and treatment with (PhSe)2 on the central square time
obtained using a software activity monitor. Data were represented as the means ± SEM of se
followed by the Duncan's test).and submerged in Hank's balanced salt solution (HBSS) containing (in
mM): 137 NaCl, 0.63 Na2HPO4, 4.17 NaHCO3, 5.36 KCl, 0.44 KH2PO4,
1.26 CaCl2, 0.41 MgSO4, 0.49 MgCl2, and 1.11 glucose, adjusted to
pH 7.2. Cerebral cortices and hippocampus were dissected, and the
slices (0.4 mm) were obtained using a Mc Illwain tissue chopper. Slices
were transferred to multiwell dishes and washed with 300 μl HBSS.
After 10 min of pre-incubation, the uptake assay was performed by
adding 16.6 nM (hippocampus) and 8.3 nM (cerebral cortices)
[3H]GABA in 300 μl HBSS at 37 °C. Incubation was terminated after
5 min (hippocampus) or 7 min (cerebral cortices) by three ice-cold
washes with 1 ml HBSS immediately followed by the addition of 0.5 M
NaOH, which was kept overnight. An aliquot of 10 μl was removed to
protein determination. Nonspeciﬁc uptake was measured using the
same protocol described above, with differences in the temperature (4
°C) and medium composition (choline chloride instead of sodium chlo-
ride). Na+-dependent uptakewas considered as the difference between
the total uptake and the nonspeciﬁc uptake. Both uptakes were per-
formed in triplicate. Incorporated radioactivity was measured using a
liquid scintillation counter (Wallac 1409). Results were expressed as
pmol of [3H]GABA uptake/mg protein/min (n = 4 animals/group).
2.2.2.2. [3H] 5-HT uptake
2.2.2.2.1. Preparation of synaptosomes. The synaptosomes were ob-
tained as described by Gray and Whittaker [34] with some modiﬁca-
tions. The cerebral cortices and hippocampi were placed into ice-cold
sucrose solution (0.32 M, pH 7.4), cut into small pieces and homoge-
nized using a glass Potter-Elvehjem tube with a Teﬂon pestle (10 up
and down strokes). The homogenate solution was centrifuged at
1000 ×g at 4 °C for 10 min in a refrigerated centrifuge. The pellet was
discarded and the supernatant was subsequently centrifuged at
12,000 ×g at 4 °C for 20 min. The ﬁnal pellet of this centrifugation was
suspended in ten volumes of ice-cold sucrose solution (0.32 M,
pH 7.4) and then used as a crude synaptosome preparation in the
[3H]5-HT uptake assay (n = 4 animals/group).
2.2.2.2.2. Uptake assay. The [3H] 5-HT uptake into synaptosomes was
carried out as described by Yura, Kiuchi [35] with some modiﬁcations.
The synaptosomal suspension (125 μg of protein) was pre-incubated
at 37 °C for 10 min in a physiological salt solution (pH 7.4, adjusted
with phosphoric acid 1%) of the following composition: 108 mM NaCl,
1 mM KCl, 27 mM NaHCO3, 1.1 mM NaH2PO4, 0.1 mM pargyline,in LAM (A). Panel B is a representative image of animal pathway in the LAM which was
ven animals per group. *p b 0.05 when compared to the control group (two-way ANOVA
Fig. 4. Effect of neonatalMSG-injection and treatmentwith (PhSe)2 on the time of freezing
in the contextual fear conditioning test. Data were represented as the means ± SEM of
seven animals per group. **p b 0.01 when compared to the control group; #p b 0.05
when compared to the MSG group (two-way ANOVA followed by the Duncan's test).
Fig. 3. Effect of neonatal MSG-injection and treatment with (PhSe)2 on the number of entries (A), the time spent (B) and the numbers of dives in the open arms (C) and the time spent in
the closed arms (D)measured in the elevated plus-maze test, in adult rats. Datawere represented as themeans± SEMof seven animals per group. *p b 0.05, **p b 0.01when compared to
the control group; #p b 0.05,##p b 0.01 when compared to the MSG group (two-way ANOVA followed by the Duncan's test).
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After preincubation, [3H] 5-HT uptake was initiated by the addition of
7 nM [3H] 5-HT (speciﬁc activity: 23 Ci/mmol) and 43 nM non-
radioactive 5-HT (total 5-HT: 50 nM, ﬁnal concentration). The synapto-
somes were incubated for a further 2 min at 37 °C. 5-HT uptake was
stopped by the immediate placement of assay tubes into ice, followed
by centrifugation at 2000 ×g at 4 °C for 5min. Final pelletswerewashed
with cold incubation buffer. Radioactivity present in pellet was mea-
sured in a scintillation counter. The non-speciﬁc activity was obtained
in the presence of 100mMparoxetine at 4 °C. Speciﬁc [3H] 5-HT uptake
was indirectly estimated by subtracting the non-speciﬁc uptake from
the total uptake determined at 37 C. Results were expressed as pmol
of [3H] 5-HT uptake/mg protein/min.
2.2.2.3. Western blot analysis. The samples of hippocampi were homoge-
nized in sodium dodecyl sulfate (SDS) 5% and protein inhibitor cocktail
(Sigma-Aldrich Company, St. Louis,Missouri, United States. The samples
(50 μg of protein) and pre stained molecular weight standards (Sigma-
Aldrich Company, St. Louis, Missouri, United States) were separated on
12% resolving with 4% concentrating SDS-PAGE electrophoresis gels.
Proteins were transferred to nitrocellulose membrane using Transfer-
Blot® Turbo™ Transfer System (1.0 mA; 0.5 h). After blocking with 5%
bovine serum albumin (BSA) solution, the blots were incubated over-
night at 4 °C with rabbit anti-BDNF (1:1000, Abcam, USA), rabbit anti-
Akt (serine/threonine protein kinase) and rabbit anti-phospho-Akt
(Ser 473) (1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Rab-
bit anti-β-tubulin (1:200, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were stained as an additional control of the protein loading.
After primary antibodies incubation, membranes were washed and in-
cubated with secondary antibodies conjugatedwith horseradish perox-
idase (1: 10,000, Bio-Rad Laboratories, Hercules, CA, USA) for 1 h at
room temperature and developed with chemiluminescence kit
(Amersham, São Paulo/Brazil). Optical density (O.D.) of the Western
blotting bands was quantiﬁed using Image J (NIH, Bethesda, MD, USA)
software for Windows. Each value was derived from the ratio between
arbitrary units obtained by the protein band and the respective β-
tubulin band (n = 3–5 animals/group). The results of Aktphosphorylation were shown by the ratio of O.D. of the phosphorylated
band/O.D. of the total band.
2.2.2.4. Protein determination. The protein concentration was deter-
mined according to Bradford [36] using bovine serum albumin (1 mg/
ml) as a standard.
2.3. Statistical analysis
The normality of data was analyzed using a D'Agostino and Pearson
omnibus K2 normality test. Data were analyzed by Two-way ANOVA
(MSG× (PhSe)2) of variance followed by the post-hoc analysis Duncan's
test, when appropriate. Main effects are presented only when the ﬁrst
order interaction was non-signiﬁcant. Descriptive statistics data were
expressed as the mean (s) ± S.E.M. Pearson's correlation coefﬁcient
was used for the estimation of correlation between BDNF levels and
AKT-phosphorylation levels. For the correlation analysis, only data
from animals of MSG and MSG + (PhSe)2 groups were used. All analy-
ses were performed using the STATISTICA for Windows software
Fig. 5.Effect of neonatalMSG-injection and treatmentwith (PhSe)2 on [3H]GABAuptake levels in samples of hippocampus (A) and cerebral cortices (B) of adult rats. Datawere represented
as themeans± SEM of four animals per group. **p b 0.01 when compared to the control group; #p b 0.05 when compared to theMSG group (two-way ANOVA followed by the Duncan's
test).
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(p b 0.05) were considered as statistically signiﬁcant.
3. Results
3.1. Behavioral tests
3.1.1. Spontaneous locomotor activity
There was no signiﬁcant difference among groups in total distance
traveled and velocity (Table 1).
In addition, two-way ANOVA of central square time revealed a sig-
niﬁcant MSG × (PhSe)2 interaction (F1,23 = 5.4844, p b 0.05). Post-hoc
analyses indicated that the administration of MSG to rats decreased
the central quadrant time when compared with that of the control
group and (PhSe)2 treatment reversed this decreased induced by MSG
(Fig.2).
3.1.2. Anxiety-like behavior
3.1.2.1. EPM test. The two-way ANOVA of the number of entries in the
open arms (F1,24 = 6.2586, p b 0.05), the time spent in the open arms
(F1,24 = 4.5026, p b 0.05), the number of dives (F1,24 = 5.9624,
p b 0.05) and the time spent in the closed arms (F1,24 = 4.8209,
p b 0.05) revealed a signiﬁcant MSG × (PhSe)2 interaction. Post-hoc
analyses indicated that the administration of MSG to rats decreased
the number of entries and the time spent in the open arms as well as
the number of dives but increased the time spent in the closed arms
when compared with those of the control group. Post-hoc analyses
also revealed that (PhSe)2 increased the number of entries and the
time spent in the open arms as well as the number of dives andFig. 6. Effect of neonatalMSG-injection and treatmentwith (PhSe)2 on [3H]5-HT uptake levels in
as the means ± SEM of four animals per group. *p b 0.05 when compared to the control group;
test).decreased the time spent in the closed arms when compared with
those of the MSG group (Fig. 3A, B, C and D).
The effects of (PhSe)2 on parameters denoting anxiolytic-like activi-
ty were independent from those reﬂecting locomotor activity [5].
3.1.2.2. Contextual fear conditioning test. During the training phase of the
contextual fear conditioning all groups showed the same freezing time.
The two-way ANOVA of freezing time revealed a signiﬁcant MSG ×
(PhSe)2 interaction (F1,24=6.5068, p b 0.05). Post-hoc analyses indicat-
ed that the time of freezingwas increased in theMSG groupwhen com-
pared to that of the control group and that (PhSe)2 treatment was
effective against this increase (Fig.4).
3.2. Ex vivo assays
3.2.1. [3H]GABA uptake
As illustrated in ﬁg. 5A, the two-way ANOVA of hippocampal GABA
uptake revealed signiﬁcant main effects of MSG (F1,12 = 11.3422,
p b 0.01) and (PhSe)2 (F1,12 = 5.6697, p b 0.05). Post hoc comparisons
demonstrated an increase in hippocampal GABA uptake induced by
MSG administration when compared with that of the control group
and (PhSe)2 was effective against this increase. No statically signiﬁcant
differences were found among the experimental groups in the cortical
GABA uptake (Fig. 5B).
3.2.2. [3H] 5-HT uptake
The two-way ANOVA of hippocampal 5-HT uptake demonstrated a
signiﬁcant MSG × (PhSe)2 interaction (F1,17 = 5.2926, p b 0.05). There
was an increase in hippocampal 5-HT uptake in rats treated with MSG
when compared with those of the control group and (PhSe)2 wassamples of hippocampus (A) and cerebral cortices (B) of adult rats. Datawere represented
#p b 0.05 when compared to the MSG group (two-way ANOVA followed by the Duncan's
Fig. 7. Effect of neonatalMSG-injection and treatmentwith (PhSe)2 on BDNF levels in hippocampus of adult rats (A). Figure B is the representation of qualitativeWestern blotting analysis.
Data were represented as the means ± SEM of three to four animals per group. *p b 0.05 when compared to the control group; #p b 0.05 when compared to the MSG group (two-way
ANOVA followed by the Duncan's test).
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was not altered in cerebral cortices of animals of any experimental
groups (Fig. 6B).
3.3. Western blot analysis
Two-way ANOVA of hippocampal levels of BDNF (F1,10= 6.3492, p b
0.05), p-Akt (F1,10=11.1392, p b 0.01) andAkt phosphorylation (p-Akt/
Aktt/tubulin) (F1,10 = 25.5133 p b 0.001) showed a signiﬁcant MSG ×
(PhSe)2 interaction. Post hoc comparisons demonstrated that the levels
of BDNF (Fig. 7A), p-Akt (Fig. 8 B) and Akt phosphorylation (Fig. 8C) de-
creased in hippocampi of rats treated with MSG when compared with
those of the control group and that (PhSe)2 was effective in increasing
the levels of these proteins. Both MSG and (PhSe)2 did not alter the
levels of total Akt in hippocampi of rats (Fig. 8A). Figs. 7B and 8D
show the representative bands of BDNF and total Akt, p-Akt and β-
tubulin, respectively. The Pearson's correlation analysis revealed a pos-
itive correlation between BDNF and p-Akt/Akt/tubulin levels (r =
0.8128, p b 0.05).Fig. 8. Effect of neonatal MSG-injection and treatment with (PhSe)2 on total Akt (A), p-Akt (B) a
themeans±SEMof three to ﬁve animals per group. *pb 0.05, **p b 0.01when compared to the
followed by the Duncan's test). Representation of qualitative Western blotting analysis (D).4. Discussion
In the present study, (PhSe)2 elicited an anxiolytic-like behavioral in
a model of MSG-induced anxiety in rats. The results provided evidence
that hippocampal GABA and 5-HT uptake and the BDNF-Akt pathway
are implicated in the anxiolytic-like effect of (PhSe)2 in rats.
In this study, the administration of MSG in neonatal rats caused cen-
tral effects, possibly by crossing the blood brain barrier, which led to an
anxiogenic-like behavioral in adult rats. The anxiogenic-like behavioral
was demonstrated by the increase in anxiogenic parameters in the ele-
vated plus maze test, a decrease of central square time in the LAM and
an increase in the time of freezing in the contextual fear conditioning
test. In addition, repeated treatment with (PhSe)2 reversed these ef-
fects, demonstrating an anxiolytic-like action of compound.
The disturbances in GABA–glutamate balance have long been in-
volved in anxiety disorders [37]. Accordingly, the current study demon-
strated that the administration of MSG increased hippocampal GABA
uptake, without changing cortical GABA uptake, which suggests a de-
crease of hippocampal GABAergic transmission. These results are innd Akt phosphorylation (C) levels in hippocampus of adult rats. Data were represented as
control group; #p b 0.05, ###p b 0.001when compared to theMSG group (two-wayANOVA
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GABAergic system by MSG, through a decrease in the GABA release
[38] and in the number of GABA-positive cells [3], besides an increase
in the GAD activity, which is related to a possible compensatory mech-
anism in the surviving GABAergic neurons in hippocampus of 60-day-
old rats [11]. Although it has been shown alterations of GABAergic
markers in cortices of rats injected with MSG, many of the effects in-
duced by MSG in the hippocampus are contrary to those observed in
the cerebral cortices [11,38] andwould explain the observed differences
in the GABA uptake among these two structures. Furthermore, Urena-
Guerrero, Orozco-Suarez [3] demonstrated a decrease of hippocampal
GABA uptake in rats treated with MSG. However, it is important to
note that the contradictory results between the previous study and
ours could be due to differences in the experimental protocol, such as
the time of exposure to MSG and regimen of treatment (continuous or
intermittent).
In the present study,MSG induced an increase of 5-HTuptake in hip-
pocampus, suggesting a decrease of cerebral serotonergic neurotrans-
mission in this structure. This result is in agreement with an early
study that showed dysfunctions of the serotonergic system in neurons
of area postrema induced by administration of MSG to neonatal rats
[14]. By contrast, our previous study demonstrated an increase of 5-
HT uptake in cerebral cortices of rats treated with MSG [6], whilst no
signiﬁcant changes in 5-HT uptakewere found in this cerebral structure
in the present study. These divergent results could be explained by dif-
ferences in the protocol regimen ofMSG treatment, whichwasﬁve days
in a previous study [6] and ten days in the present one.
The 5-HT system plays a role in anxiety, an increased availability of
5-HT or a higher postsynaptic 5-HT receptor activity is responsible for
anxiolytic effects, while a decrease in efﬁciency of 5-HT induces anxiety
[39]. Then, one hypothesis to explain the anxiolytic-like action induced
by (PhSe)2 could be the inhibition of the 5-HT uptake in hippocampus.
The effect of (PhSe)2 inmodulating 5-HT and GABA uptake observed
in this study is in agreement with a previous study that demonstrated
that anxiolytic-like action of (PhSe)2 involves its interaction with
GABA-A and 5-HT receptors [27]. In this sense, it is well known that
the inhibition of GABA uptake is used in the treatment of some psychi-
atric disorders, including anxiety [40]. Studies indicate that acute or
chronic administration of tiagabine, a GABA reuptake inhibitor, de-
creases anxiety-related behavior in rodents [41]. Moreover, selective
5-HT reuptake inhibitors (SSRIs) have been also effective as anxiolytic
drugs for long-term therapy [42]. In this context, the results of this
study further expand the knowledge about the mechanisms by which
(PhSe)2 modulates GABAergic and serotonergic systems to exert
anxiolytic-like effect.
The exposure to high concentrations of MSG early in life induces cell
death and changes in the cytoarchitecture of the surviving pyramidal
neurons of the hippocampal CA1 [43], conﬁrming that hippocampus is
of the target structures of MSG early in life. Accordingly, all neurochem-
ical alterations induced by MSG in the present study were found in the
hippocampus. Previous studies revealed a bidirectional relationship be-
tween GABA and 5-HT systems [44], once these systems are closely
interlinked, neuroanatomically and functionally [45]. Considering the
relationship between GABA and 5-HT systems, the anxiety-like behav-
ior induced by MSG demonstrated in this study could be, at least in
part, related to the increase in the hippocampal GABA and 5-HT uptake.
Although clinical studies have revealed that the dysregulation of se-
rotonergic and GABAergic systems is important in the pathogenesis of
anxiety disorders, among several hypotheses [46,47] evidence have
identiﬁed modiﬁcations of intracellular signaling proteins and target
genes that could also contribute to thepharmacological action of antide-
pressant and anxiolytic therapy [48,49]. In this sense, a reduction of
BDNF signaling has been implicated in the pathophysiology of both bi-
polar and anxiety disorders [15,50] as well as early life traumas can in-
duce downregulation of BDNF mRNA and protein levels in the CA1
subregion of hippocampus [51], a target region of MSG in the neonatalperiod. Therefore, an important result revealed in the present study
was the decrease of hippocampal BDNF levels induced by early life ex-
posure to MSG, which suggests that a modulation of BDNF levels can
be involved in anxiety-like behavior induced by MSG early in life.
It has been also reported that the TrkB activation by BDNF stimulates
the Akt phosphorylation [18]. Given that MSG induced a decrease in p-
Akt and Akt phosphorylation levels, it is possible that the low levels of
BDNF bound to the TrkB receptor, would lead to a low activation of
Akt when MSG is administered to rats. Corroborating this, a positive
Pearson's correlation was found between the levels of BDNF and Akt
phosphorylation. Furthermore, Akt has been proposed to be a conver-
gence point for diverse survival signals [52]. Therefore, the decrease in
Akt phosphorylation levels could be related to death of neuronal cell in-
duced by MSG [43]. In addition, (PhSe)2 treatment was effective in re-
versing the increase in the levels of BDNF, p-Akt and Akt
phosphorylation induced by MSG, indicating that this signaling path-
way can be the new target for the anxiolytic-like effect of (PhSe)2.
We assume as potential limitation of this study the use of both male
and female rats, which might be a possible confounding factor in this
study [53,54].
5. Conclusion
Considering what was mentioned above, our ﬁndings illustrate the
potential anxiolytic-like of (PhSe)2 in adult rats exposed to MSG during
their neonatal period and suggest that this effect is likely to bemediated
by themodulation of hippocampal GABA and 5-HT uptake aswell as the
BDNF-Akt pathway.
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